<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxacillin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxacillin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxacillin: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11817" href="/d/html/11817.html" rel="external">see "Oxacillin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12663" href="/d/html/12663.html" rel="external">see "Oxacillin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F204217"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Penicillin</li></ul></div>
<div class="block doa drugH1Div" id="F204193"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Usual dosage range: IV: </b>1 to 2 g every 4 to 6 hours; may also administer total daily dose as a continuous infusion over 24 hours (eg, for a dose of 2 g every 4 hours, administer 12 g over 24 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19258261','lexi-content-ref-26229122','lexi-content-ref-19245363','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19258261','lexi-content-ref-26229122','lexi-content-ref-19245363','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection:</b>
<i>Pathogen-directed therapy for methicillin-susceptible staphylococci (off label):</i>
<b>IV:</b> 2 g every 4 hours; treat uncomplicated bacteremia for ≥14 days starting from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment:</b>
<i>Pathogen-directed therapy for methicillin-susceptible staphylococci (off label):</i></p>
<p style="text-indent:-2em;margin-left:4em;">Native valve: <b>IV:</b> 12 g/day in 4 or 6 divided doses (ie, 2 g every 4 hours or 3 g every 6 hours) for 6 weeks. For uncomplicated right-sided ineffective endocarditis, 2 weeks of therapy may be adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Prosthetic valve: <b>IV:</b> 12 g/day in 6 divided doses (ie, 2 g every 4 hours) for ≥6 weeks; use with rifampin for entire duration of therapy and gentamicin for first 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial:</b>
<i>Pathogen-directed therapy for methicillin-susceptible staphylococci (off label):</i>
<b>IV:</b> 2 g every 4 hours; consider addition of rifampin if organism is susceptible and prosthetic material is present. Treatment duration is 10 to 14 days, depending on causative pathogen(s) and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c92ca38-0c20-4ec4-b5f0-113c6ccf7cd2">Osteomyelitis and/or discitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis and/or discitis:</b>
<i>Pathogen-directed therapy for methicillin-susceptible staphylococci </i>
<i>(off label)</i>: <b>IV:</b> 1.5 to 2 g every 4 to 6 hours or via continuous infusion for ≥6 weeks depending on extent of infection, debridement, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia:</b>
<i>Pathogen-directed therapy for methicillin-susceptible S. aureus (off label): </i>
<b>IV:</b> 2 g every 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.1'])">Ref</a></span>). Minimum duration is generally 5 days for community-acquired pneumonia and 7 days for hospital-acquired or ventilator-associated pneumonia; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577','lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577','lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection:</b>
<i>Pathogen-directed therapy for methicillin-susceptible staphylococci (off label): </i>
<b>IV:</b> 1.5 to 2 g every 4 to 6 hours; duration ranges from 2 to 6 weeks depending on prosthesis management, use of rifampin, and other patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cellulitis (nonpurulent) in patients without risk for methicillin-resistant S. aureus:</i>
<b>IV:</b> 1 to 2 g every 4 hours. Total duration of therapy is ≥5 days (including oral step-down therapy); may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Necrotizing infection due to methicillin-susceptible S. aureus (MSSA) (off label): </i>
<b>IV:</b> 1 to 2 g every 4 hours; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical site incisional infection (trunk or extremity, not involving axilla or perineum) (off label):</i>
<b>IV:</b> 2 g every 6 hours; duration is dependent upon severity, need for debridement, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990570"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥10 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1','lexi-content-ref-expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1','lexi-content-ref-expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: No specific dosage adjustment recommended; however, monitor closely as high oxacillin concentrations and neurotoxicity have been reported in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28332157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28332157'])">Ref</a></span>). When treating less severe infections, a maximum daily dose of 8 g/day may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intermittent hemodialysis (thrice weekly): </b>Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14085025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14085025'])">Ref</a></span>): No specific dosage adjustment recommended; however, monitor closely as high oxacillin concentrations and neurotoxicity have been reported in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28332157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28332157'])">Ref</a></span>). When treating less severe infections, a maximum daily dose of 8 g/day may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Minimally dialyzed (5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5903164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5903164'])">Ref</a></span>): No specific dosage adjustment recommended; however, monitor closely as high oxacillin concentrations and neurotoxicity have been reported in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28332157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28332157'])">Ref</a></span>). When treating less severe infections, a maximum daily dose of 8 g/day may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1','lexi-content-ref-expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1','lexi-content-ref-expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987925"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F204194"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. <b>Note:</b> May contain a significant amount of sodium; consult product specific labeling for amount. Older adults may respond with a blunted natriuresis to salt loading. This may be clinically important in diseases such as congestive heart failure.</p></div>
<div class="block dop drugH1Div" id="F204208"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12663" href="/d/html/12663.html" rel="external">see "Oxacillin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: IV, IM: 100 to 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment:</b> Children and Adolescents: IV: 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g/day</b>. Treat for at least 4 to 6 weeks; duration should be individualized based on presentation, valve type, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6af3440a-28f0-496d-97e9-ea9ece98c109">Meningitis/Ventriculitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis/Ventriculitis:</b> Infants, Children, and Adolescents: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5285a396-852e-4b3d-b4b0-d754f216f7be">Osteoarticular infection, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarticular infection, acute (eg, septic arthritis, osteomyelitis):</b> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day divided every 4 to 6 hours; maximum daily dose: 12 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-28708801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-28708801'])">Ref</a></span>). May transition to oral therapy as appropriate (eg, response to initial parenteral therapy, oral option available). Minimum total duration is 2 to 3 weeks for septic arthritis and 3 to 4 weeks for osteomyelitis; however, duration should be individualized based on several factors, including causative pathogen, response to therapy, and normalization of inflammatory markers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28708801','lexi-content-ref-34350458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28708801','lexi-content-ref-34350458'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6daf0c18-c158-4c8f-8b0c-4bfe288cfe7d">Pneumonia, community-acquired moderate to severe infection, methicillin-susceptible <i>Staphylococcus aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (CAP) moderate to severe infection, methicillin-susceptible <i>Staphylococcus aureus </i>(MSSA):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 months, Children, and Adolescents: IV: 150 to 200 mg/kg/day divided every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>)<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>MSSA (non-necrotizing infection):</i> IV: 100 to 150 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g/day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Necrotizing infection due to MSSA:</i> IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day;</b> continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51151032"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, IM: There are no dosage adjustments provided in the manufacturer's labeling; however, oxacillin is eliminated via the kidney; monitoring is recommended. High oxacillin concentrations and neurotoxicity have been reported in adult patients with severe kidney impairment; monitor closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28332157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28332157'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis: </b>Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14085025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14085025'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, IM: No specific dosage adjustment recommended; however, high oxacillin concentrations and neurotoxicity have been reported in adult patients with severe kidney impairment; monitor closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28332157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28332157'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Minimally dialyzed (5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5903164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5903164'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, IM: No specific dosage adjustment recommended; however, high oxacillin concentrations and neurotoxicity have been reported in adult patients with severe kidney impairment; monitor closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28332157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28332157'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51151033"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F204158"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> associated diarrhea, <i>clostridioides difficile</i> colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis, acute renal tubular disease</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Drug reaction with eosinophilia and systemic symptoms (Sharpe 2019)</p></div>
<div class="block coi drugH1Div" id="F204174"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity (eg, anaphylaxis) to oxacillin, any penicillin, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F204155"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic/hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in patients with histories of significant allergies and/or asthma; discontinue treatment and institute appropriate therapy if an allergic reaction occurs</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis: Acute hepatitis and reversible elevations of serum transaminases have been reported sometimes accompanied by rash and leukopenia; onset after 2 to 3 weeks of therapy (Dahlgren 1997; Faden 2009; Maraqa 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: May contain a significant amount of sodium; consult product specific labeling for amount. Older adults may respond with a blunted natriuresis to salt loading. This may be clinically important in diseases such as congestive heart failure.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878570"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Hepatotoxicity and rash are more common with oxacillin compared to other parenteral antibiotics; in a study of pediatric patients (5 to 19 years) receiving outpatient parenteral antimicrobial therapy (oxacillin n=41; nafcillin n=58; "other" antibiotics n=146), significantly more hepatotoxicity (22%) and rash (31.7%) were reported in the oxacillin group compared to the nafcillin group (0% and 10.3%) or other antibiotics (1.4% and 1.4%) (Maraqa 2002).</p></div>
<div class="block foc drugH1Div" id="F204167"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/50 mL (50 mL); 2 g/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F204151"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323563"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Oxacillin Sodium in Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 gm/50 mL (per mL): $0.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 gm/50 mL (per mL): $0.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Oxacillin Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $13.50 - $14.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $10.80 - $29.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Oxacillin Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g (per each): $66.30 - $145.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F204171"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer IVP over 10 minutes or IVPB over 30 minutes. Total daily dose may also be administered over 24 hours as a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19258261','lexi-content-ref-26229122','lexi-content-ref-19245363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19258261','lexi-content-ref-26229122','lexi-content-ref-19245363'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613482"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer by deep IM injection into a large muscle mass (eg, gluteus maximus); avoid sciatic nerve injury.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Direct IV injection: Administer over 10 minutes at a concentration of 100 mg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Administer over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10318297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10318297'])">Ref</a></span>); extending the infusion over 60 minutes has been used for peripheral administration by some ambulatory centers to decrease the risk of phlebitis in home care patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9161625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9161625'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F204170"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Staphylococcal infections:</b> Treatment of infections caused by penicillinase-producing staphylococci that have demonstrated susceptibility to the drug; empiric therapy in suspected cases of resistant staphylococcal infections.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Limitations of use: Oxacillin should not be used in infections caused by organisms susceptible to penicillin G.</p></div>
<div class="block off-label drugH1Div" id="F26191114"><span class="drugH1">Use: Off-Label: Adult</span><p>Surgical site incisional infection</p></div>
<div class="block cyt drugH1Div" id="F13299797"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F204160"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F204176"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Oxacillin crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Although it is highly protein bound, therapeutic concentrations can be found in the amniotic fluid following IV administration (Nau 1987).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Czeizel 1999; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).</p></div>
<div class="block brc drugH1Div" id="F204177"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Oxacillin is present in breast milk (Prigot 1962).</p>
<p style="text-indent:-2em;margin-left:2em;">Concentrations of penicillin class antibiotics in breast milk are limited (Nau 1987). The manufacturer recommends that caution be exercised when administering oxacillin to breastfeeding women. In general, antibiotics that are present in breast milk may cause non–dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F204178"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F204165"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for signs and symptoms of anaphylaxis during first dose; monitor periodic CBC, urinalysis, BUN, serum creatinine, AST and ALT</p></div>
<div class="block pha drugH1Div" id="F204154"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F204173"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Into bile, pleural fluids; insignificant concentrations in CSF and aqueous humor.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~94% (mainly albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates (PNA: 8 to 15 days): 96 minutes (Axline 1967).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates &gt;1 week of age, Infants, and Children ≤2 years: 78 minutes; range: 53 to 109 minutes (Burckhart 1978).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 20 to 30 minutes; prolonged with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: 30 minutes; IV: 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and bile (unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F55859663"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent, associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC); goal: ≥50% <i>f</i>T &gt; MIC (bactericidal) (Drusano 2003; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Critically ill patients in the ICU: Minimum goal: ≥50% <i>f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% <i>f</i>T &gt; 4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Expected drug exposure:</p>
<p style="text-indent:-2em;margin-left:6em;">C<sub>max </sub>(peak): Single dose: IV: Adults: 500 mg: 43 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Minimal bacterial killing continues after concentration of penicillins fall below the MIC of targeted pathogen and varies based on the organism:</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-positive cocci: 1.5 to 3.5 hours (Craig 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-negative bacilli: 0 to 1.5 hours (Craig 1991).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038712"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Prostaphlin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Penstapho</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Bristopen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Oxacilin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bactocilin | Oxacilil | Oxacilina | Oxacilina sodica | Oxanon | Oxapen | Prodoxacilina | Staficilin n | Teutocilin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Oxacare</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Oxacillin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Oxacidelt | Oxacil | Oxacilina | Prostafilina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Oxacilin | Oxacilina atb | Prostaphlin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Infectostaph</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Prostafilina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Oxacilina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Oxacilina Antibiotice | Oxacillin | Oxacillin natrium | Prostaphlin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bristopen | Istopen | Oxacilline Panpharma</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Prostaphlin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Prostaphlin | Staphcillin v</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Oxacilin | Oxacillin | Oxacillin natrium | Oxin | Pan oxacillin | Prostaphlin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Penstapho</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Oxacilin | Oxacilina | Oxacillin | Oxacillin natrium | Oxin | Prostaphlin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Bristopen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dicloxal ox | Oxacilina | Oxalin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bactocill | Cilvex | Oxal | Oxan | Oxapen | Oxatalis | Panadox | Peoxa | Pharmawealth oxacillin | Prostaphlin | Stafcil | Wydox | Yss oxacillin sodium</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Oxacilin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Oxacillin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Oxacilin lasca | Oxacilina dutriec | Oxacilina nortelab | Oxameg</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Oxacilina atb | Oxacillin Atb</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Oxacillin | Prostaphlin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Prostaphlin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Oxacilin | Prostaphlin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Prostaphlin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bristopen | Oxacil | Staphymicine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ocillina | Oxacillin | Prostaphlin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Oxacillin | Oxacillin natrium</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Oxacilina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Biocilina | Oxacilina | Oxawell | Oxiclin | Oxipen | Prostafilina</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper.<i> Intensive Care Med</i>. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al; the National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910809">
<a name="32910809"></a>Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. <i>J Antimicrob Chemother</i>. 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/32910809/pubmed" id="32910809" target="_blank">32910809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6016648">
<a name="6016648"></a>Axline SG, Yaffe SJ, Simon HJ. Clinical pharmacology of antimicrobials in premature infants. II. Ampicillin, methicillin, oxacillin, neomycin, and colistin. <i>Pediatrics</i>. 1967;39(1):97-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/6016648/pubmed" id="6016648" target="_blank">6016648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14085025">
<a name="14085025"></a>Bulger RJ, Lindholm DD, Murray JS, Kirby WM. Effect of uremia on methicillin and oxacillin blood levels. <i>JAMA</i>. 1964;187:319-322. doi:10.1001/jama.1964.03060180005001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/14085025/pubmed" id="14085025" target="_blank">14085025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-707507">
<a name="707507"></a>Burckart GJ, Evans WE, Whitington GL. Comparison of antibiotic serum concentrations after intramuscular oxacillin and oral cloxacillin in children. <i>Am J Hosp Pharm</i>. 1978;35(11):1380-1382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/707507/pubmed" id="707507" target="_blank">707507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>Clin Microbiology Newsletter.</i> 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10482063">
<a name="10482063"></a>Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Teratogenic evaluation of oxacillin. <i>Scand J Infect Dis</i>. 1999;31(3):311-312. doi:10.1080/00365549950163635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/10482063/pubmed" id="10482063" target="_blank">10482063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9161625">
<a name="9161625"></a>Dahlgren A. Adverse drug reactions in home care patients receiving nafcillin or oxacillin. <i>Am J Health-Syst Pharm</i>. 1997;54(10):1176-1179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/9161625/pubmed" id="9161625" target="_blank">9161625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12516029">
<a name="12516029"></a>Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. <i>Clin Infect Dis.</i> 2003;36(suppl 1):S42-S50. doi:10.1086/344653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/12516029/pubmed" id="12516029" target="_blank">12516029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.DOR">
<a name="expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19483522">
<a name="19483522"></a>Faden D, Faden HS. The high rate of adverse drug events in children receiving prolonged outpatient parenteral antibiotic therapy for osteomyelitis. <i>Pediatr Inf Dis J</i>. 2009;28(6):539-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/19483522/pubmed" id="19483522" target="_blank">19483522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.1">
<a name="Golightly.1"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys. </i>Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care.</i> 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19258261">
<a name="19258261"></a>Hughes DW, Frei CR, Maxwell PR, et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. <i>Antimicrob Agents Chemother</i>. 2009;53(5):2014-2019. doi:10.1128/AAC.01232-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/19258261/pubmed" id="19258261" target="_blank">19258261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.1">
<a name="Klompas.1"></a>Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11731945">
<a name="11731945"></a>Maraqa NF, Gomez MM, Rathore HH, et al. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. <i>Clin Inf Dis</i>. 2002;34(1):50-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/11731945/pubmed" id="11731945" target="_blank">11731945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Disease Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3301235">
<a name="3301235"></a>Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. <i>Dev Pharmacol Ther</i>. 1987;10(3):174-198. doi:10.1159/000457744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/3301235/pubmed" id="3301235" target="_blank">3301235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28332157">
<a name="28332157"></a>Neuville M, El-Helali N, Magalhaes E, et al. Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects. <i>Ann Intensive Care</i>. 2017;7(1):34. doi:10.1186/s13613-017-0255-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/28332157/pubmed" id="28332157" target="_blank">28332157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-978335">
<a name="978335"></a>Olans RN and Weiner LB, “Reversible Oxacillin Hepatotoxicity,” <i>J Pediatr</i>, 1976, 89(5):835-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/978335/pubmed" id="978335" target="_blank">978335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al, “Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,” <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxacillin.1">
<a name="Oxacillin.1"></a>Oxacillin [prescribing information]. Princeton, NJ: Sandoz Inc; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxacillin.2">
<a name="Oxacillin.2"></a>Oxacillin for Injection [prescribing information]. Bethlehem, PA: Piramal Critical Care; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxacillin.3">
<a name="Oxacillin.3"></a>Oxacillin for Injection (1g, 2g, and 10g) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxacillin.4">
<a name="Oxacillin.4"></a>Oxacillin Injection [prescribing information]. Deerfield, IL: Baxter Healthcare; received March 7, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prigot.1">
<a name="Prigot.1"></a>Prigot A, Froix C, Rubin E. Absorption, distribution, and excretion of a new penicillin, oxacillin. <i>Antimicrob Agents Chemother</i>. 1962:402-410.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis.</i> 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3428165">
<a name="3428165"></a>Robinson DC, Cookson TL, and Grisafe JA, "Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients," <i>Drug Intell Clin Pharm</i>, 1987, 21(12):985-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/3428165/pubmed" id="3428165" target="_blank">3428165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5903164">
<a name="5903164"></a>Ruedy J. The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease. <i>Can Med Assoc J</i>. 1966;94(6):257-261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/5903164/pubmed" id="5903164" target="_blank">5903164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708801">
<a name="28708801"></a>Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. <i>Pediatr Infect Dis J</i>. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/28708801/pubmed" id="28708801" target="_blank">28708801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19245363">
<a name="19245363"></a>Schuster KM, Wilson D, Schulman CI, Pizano LR, Ward CG, Namias N. Continuous-infusion oxacillin for the treatment of burn wound cellulitis. <i>Surg Infect (Larchmt)</i>. 2009;10(1):41-45. doi:10.1089/sur.2007.081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/19245363/pubmed" id="19245363" target="_blank">19245363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30877266">
<a name="30877266"></a>Sharpe A, Mourad BM, Hardwick CJ, et al. Oxacillin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Am J Case Rep</i>. 2019;20:345-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/30877266/pubmed" id="30877266" target="_blank">30877266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis [published online February 14, 2017]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis</i>. 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34350458">
<a name="34350458"></a>Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (PIDS/IDSA): 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. <i>J Pediatric Infect Dis Soc</i>. 2021;10(8):801-844. doi:10.1093/jpids/piab027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/34350458/pubmed" id="34350458" target="_blank">34350458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10090000">
<a name="10090000"></a>Wright AJ, “The Penicillins,” <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/10090000/pubmed" id="10090000" target="_blank">10090000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2254575">
<a name="2254575"></a>Yoshikawa TT, “Antimicrobial Therapy for the Elderly Patient,” <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/2254575/pubmed" id="2254575" target="_blank">2254575</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9724 Version 321.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
